Mavik is a drug owned by Abbvie Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 28, 2015. Details of Mavik's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5744496 | Method of treating cardiac insufficiency using angiotensin-converting enzyme inhibitors |
Apr, 2015
(9 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Mavik is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Mavik's family patents as well as insights into ongoing legal events on those patents.
Mavik's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Mavik's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 28, 2015 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Mavik Generic API suppliers:
Trandolapril is the generic name for the brand Mavik. 10 different companies have already filed for the generic of Mavik, with Aurobindo Pharma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Mavik's generic
How can I launch a generic of Mavik before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Mavik's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Mavik's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Mavik -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 1 mg, 2 mg and 4 mg | 04 Oct, 2004 | 1 | 12 Jun, 2007 | 12 Jun, 2007 | Extinguished |
Alternative Brands for Mavik
Mavik which is used for treating congestive heart failure., has several other brand drugs using the same active ingredient (Trandolapril). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Abbvie |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Trandolapril, Mavik's active ingredient. Check the complete list of approved generic manufacturers for Mavik
About Mavik
Mavik is a drug owned by Abbvie Inc. It is used for treating congestive heart failure. Mavik uses Trandolapril as an active ingredient. Mavik was launched by Abbvie in 1996.
Approval Date:
Mavik was approved by FDA for market use on 26 April, 1996.
Active Ingredient:
Mavik uses Trandolapril as the active ingredient. Check out other Drugs and Companies using Trandolapril ingredient
Treatment:
Mavik is used for treating congestive heart failure.
Dosage:
Mavik is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET | Discontinued | ORAL |
| 1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET | Discontinued | ORAL |
| 4MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET | Discontinued | ORAL |